CFDE Data Portal | Search G3BP1P1

	Label	Description
	G3BP1P1 Gene (Entity type)	ENSG00000235651 - G3BP1 pseudogene 1
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236502 paclitaxel 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 13 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Esophagus 20-29 vs 50-59 Up Gene Set (Entity type)	A Gene Set from GTEx

G3BP1P1

ENSG00000235651 - G3BP1 pseudogene 1

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

A Gene Set from LINCS

GSE236502 paclitaxel 2 v 3 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 13 human dn

A Gene Set from LINCS

GSE239844 crizotinib 4 v 10 human dn

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human dn

A Gene Set from LINCS

GSE146358 dopamine 3 v 2 human dn

A Gene Set from LINCS

GTEx Esophagus 20-29 vs 50-59 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.